New drug cocktail aims to halt prostate Cancer's return

NCT ID NCT01251861

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding an experimental drug (MK-2206) to the standard hormone therapy bicalutamide can better control prostate cancer in men whose PSA levels are rising after initial treatment. About 108 men with recurrent prostate cancer took part. The goal was to see if the combination could lower PSA to undetectable levels or slow the cancer's growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: bicalutamide and Akt inhibitor MK2206
What this could lead to: If successful, this combination could offer a new way to delay prostate cancer progression in men with rising PSA after initial therapy.
What could go wrong: This is a phase II trial with only 108 participants, so results may not apply to all patients. The combination may cause side effects and may not improve outcomes over bicalutamide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

108 people

The number who actually took part.

Started

Mar 2011

Finished

May 2026

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must have histologically confirmed diagnosis of prostate cancer * Patient must have had previous treatment with definitive surgery or radiation therapy or cryoablation * Patient may have prior salvage therapy (surgery, radiation or other local ablative procedures) within 4 weeks prior to randomization if the intent was for cure; prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to randomization is allowed * Patient must have no evidence of metastatic disease on physical exam, computed tomography (CT) abdomen/pelvis (or magnetic resonance imaging \[MRI\]), chest x-ray (or CT chest) and bone scan within 8 weeks prior to randomization * Patient may have had prior neoadjuvant and/or adjuvant therapy (chemotherapy, vaccines or experimental agents) within 4 weeks prior to randomization, if the PSA rise and PSA doubling time (PSADT) were documented after the testosterone level was \> 150 ng/dL * Patient may not have had therapy modulating testosterone levels (such as luteinizing-hormone, releasing-hormone agonists/antagonists and antiandrogens) within 1 year prior to randomization, unless it was in the neoadjuvant and/or adjuvant setting; agents such as 5 alpha reductase inhibitors, ketoconazole, abiraterone, systemic steroids, or herbal supplements known to decrease PSA levels including any dose of megestrol acetate, finasteride (e.g., Saw Palmetto and PC-SPES, African pygeum extract, lycopene, alanine, glutamic acid and glycine, beta-sitosterol, lycopene, nettle root extract, quercitin, Belizian Man Vine extract, mulra puama extract and epimedium extract campesterol, beta-sitosterol, stigmasterol, sitostanol and brassicasterol) are not permitted at any time during the period that the PSA values are being collected * Patient must have hormone-sensitive prostate cancer as evident by a serum total testosterone level \> 150 ng/dL within 12 weeks prior to randomization * Patient must have evidence of biochemical failure after primary therapy and subsequent progression * Biochemical failure is declared when the PSA reaches a threshold value after primary treatment and it differs for radical prostatectomy or radiation therapy * For radical prostatectomy the threshold for this study is PSA \>= 0.4 ng/mL * For radiation therapy the threshold is a PSA rise of 2 ng/mL above the nadir PSA achieved post radiation with or without hormone therapy (2006 Radiation Therapy Oncology Group \[RTOG\]-American Society for Radiation Oncology \[ASTRO\] Consensus definition) * PSA progression requires a PSA rise above the threshold (PSA1) measured at any time point since the threshold was reached * The PSADT must be \< 12 months; requires two consecutive PSA rises (PSA2 and PSA3) above the PSA1; PSA2 and PSA3 must be obtained within 6 months of study entry; all baseline PSAs should be obtained, preferably, at the same reference lab * PSADT calculation needs 3 PSA values: * PSA1 is any PSA value that is equal or greater than the threshold PSA (0.4 ng/mL for radical prostatectomy or 2 ng/mL above the nadir for primary radiation therapy) indicating biochemical relapse * PSA2 must be higher than PSA1, obtained at least 2 weeks after PSA1 and within 6 months or less from randomization * PSA3 must be higher than PSA2 and obtained at least 2 weeks after PSA2 * Baseline PSA must have reached a minimum of 2 ng/mL but be no greater than 50 ng/mL and equal or higher than PSA3; PSA3 may be used as baseline PSA if obtained within 1 week of randomization * Patient's PSA doubling time (PSADT) must be less than 12 months * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Granulocytes \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Serum creatinine within normal institutional limits or creatinine clearance \>= 50 ml/min for patients with creatinine levels above institutional normal * Serum total bilirubin =\< 1.5 times upper limit of normal (ULN) * Alkaline phosphatase (ALP) =\< 2.5 x ULN * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 2.5 x institutional upper limit of normal * Human immunodeficiency virus (HIV)-positive patients are excluded from this study * Patient cannot receive concurrent therapeutic administration of anticoagulant therapy; low dosage aspirin =\< 325 mg per day is allowed * Patients with impaired cardiac function including any one of the following will be excluded from entry on study: * Baseline corrected QT interval (QTc) \> 450 msec (male) (patients with QTc 450-480 msec will be allowed to participate in this trial if they do not have any of the other cardiac conditions mentioned in this section) * Patients with congenital long QT syndrome * History of sustained ventricular tachycardia * Any history of ventricular fibrillation or torsades de pointes * Concomitant use of drugs with a risk of causing torsades de pointes * Bradycardia defined as heart rate \< 50 beats per minute; patients with a pacemaker and heart rate \>= 50 beats per minute are eligible * Myocardial infarction or unstable angina within 6 months of study entry * Congestive heart failure (New York Heart Association class III or IV) * Right bundle branch block and left anterior hemi-block (bifascicular block) * Patient must not have gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis) * Patient may not be receiving any other investigational agents or receiving concurrent anticancer therapy (chemotherapy, immunotherapy, radiation therapy, surgery for cancer, or experimental medications) at time of randomization * Patient may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or bicalutamide * Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients with diabetes or at risk for hyperglycemia MUST not be excluded from trials with MK-2206, but the hyperglycemia should be well controlled before the patient enters the trial * Patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible * Patient must NOT have previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions: * Basal cell or squamous cell carcinoma of the skin OR * Prior malignancy has been adequately treated and patient has been continuously disease free for \>= 2 years * Patient must agree to use barrier contraception during and for 3 months after discontinuation of study treatment; if patient impregnates a woman while on treatment or within 3 months of discontinuing treatment, he should inform his treating physician immediately * Patients must discontinue use of enzyme-inducing anti-epileptic drugs (EIAEDs) \>= 14 days prior to study enrollment; the investigator may prescribe non-EIAEDs; patients who must begin EIAED therapy while on study will be allowed to remain * Patients must not be taking cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital), St John's Wort, ketoconazole, dexamethasone, the dysrhythmic drugs (terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, indapamide or flecainide), haloperidol, risperidone, rifampin, grapefruit, or grapefruit juice within two weeks of randomization and during the course of therapy * Patients may have received targeted agents (angiogenesis inhibitors, epidermal growth factor receptor \[EGFR\] inhibitors, mammalian target of rapamycin \[mTOR\] inhibitors, phosphatidylinositol 3 kinase \[PI3K\] inhibitors, etc.), however patients must have discontinued treatment with the targeted agent(s) at least 4 weeks prior to enrollment; if the patient stopped targeted agent(s) due to unresolved or persistent grade 3 or 4 toxicity, patient cannot be enrolled onto the study regardless of the length of time since discontinuation of treatment with targeted agent(s)

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent prostate carcinoma Stage I prostate cancer ajcc V7 Stage IIA prostate cancer ajcc V7 Stage IIB prostate cancer ajcc V7 Stage III prostate cancer ajcc V7

Contacts and locations

Locations

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407, United States
AdventHealth Littleton

Littleton, Colorado, 80122, United States
AdventHealth Parker

Parker, Colorado, 80138, United States
AdventHealth Porter

Denver, Colorado, 80210, United States
Allegiance Health

Jackson, Michigan, 49201, United States
Aspirus Cancer Care - Wisconsin Rapids

Wisconsin Rapids, Wisconsin, 54494, United States
Atlanta VA Medical Center

Decatur, Georgia, 30033, United States
Banner North Colorado Medical Center

Greeley, Colorado, 80631, United States
Banner North Colorado Medical Center - Loveland Campus

Loveland, Colorado, 80539, United States
Bay Area Medical Center

Marinette, Wisconsin, 54143, United States
Baystate Medical Center

Springfield, Massachusetts, 01199, United States
Beacon Kalamazoo

Kalamazoo, Michigan, 49048, United States
Beebe Medical Center

Lewes, Delaware, 19958, United States
Bixby Medical Center

Adrian, Michigan, 49221, United States
Boulder Community Foothills Hospital

Boulder, Colorado, 80303, United States
Bronson Methodist Hospital

Kalamazoo, Michigan, 49007, United States
Butler Memorial Hospital

Butler, Pennsylvania, 16001, United States
Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017, United States
Carle BroMenn Medical Center

Normal, Illinois, 61761, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carle Cancer Institute Normal

Normal, Illinois, 61761, United States
Christiana Care - Union Hospital

Elkton, Maryland, 21921, United States
Christiana Care Health System-Christiana Hospital

Newark, Delaware, 19718, United States
CommonSpirit Saint Anthony Hospital Cancer Center

Lakewood, Colorado, 80228, United States
Community Howard Regional Health

Kokomo, Indiana, 46904, United States
Cooper Hospital University Medical Center

Camden, New Jersey, 08103, United States
Corewell Health Dearborn Hospital

Dearborn, Michigan, 48124, United States
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085, United States
Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph, Michigan, 49085, United States
Cork University Hospital

Cork, Ireland
Decatur Memorial Hospital

Decatur, Illinois, 62526, United States
Elkhart General Hospital

Elkhart, Indiana, 46515, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Essentia Health Cancer Center

Duluth, Minnesota, 55805, United States
Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401, United States
Essentia Health Saint Mary's Medical Center

Duluth, Minnesota, 55805, United States
Eureka Hospital

Eureka, Illinois, 61530, United States
Fairview Ridges Hospital

Burnsville, Minnesota, 55337, United States
Fairview Southdale Hospital

Edina, Minnesota, 55435, United States
Fisher-Titus Medical Center

Norwalk, Ohio, 44857, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Franciscan Saint Anthony Health-Michigan City

Michigan City, Indiana, 46360, United States
Fredericksburg Oncology Inc

Fredericksburg, Virginia, 22401, United States
Fulton County Health Center

Wauseon, Ohio, 43567, United States
Geisinger Medical Center

Danville, Pennsylvania, 17822, United States
Geisinger Medical Center-Cancer Center Hazleton

Hazleton, Pennsylvania, 18201, United States
Geisinger Medical Group

State College, Pennsylvania, 16801, United States
Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre, Pennsylvania, 18711, United States
Genesys Hurley Cancer Institute

Flint, Michigan, 48503, United States
Genesys Regional Medical Center-West Flint Campus

Flint, Michigan, 48532, United States
Graham Hospital Association

Canton, Illinois, 61520, United States
HSHS Saint Nicholas Hospital

Sheboygan, Wisconsin, 53081, United States
Heartland Cancer Research NCORP

Decatur, Illinois, 62526, United States
Hematology Oncology Associates

Albuquerque, New Mexico, 87106, United States
Hematology Oncology Center Incorporated

Elyria, Ohio, 44035, United States
Hennepin County Medical Center

Minneapolis, Minnesota, 55415, United States
Henry Ford Health Saint John Hospital

Detroit, Michigan, 48236, United States
Henry Ford Health Warren Hospital

Warren, Michigan, 48093, United States
Hickman Cancer Center

Adrian, Michigan, 49221, United States
Hinsdale Hematology Oncology Associates Incorporated

Hinsdale, Illinois, 60521, United States
Holy Family Memorial Hospital

Manitowoc, Wisconsin, 54221, United States
Horizon Oncology Research LLC

Lafayette, Indiana, 47905, United States
Hurley Medical Center

Flint, Michigan, 48503, United States
Hutchinson Area Health Care

Hutchinson, Minnesota, 55350, United States
IU Health Central Indiana Cancer Centers-East

Indianapolis, Indiana, 46219, United States
IU Health La Porte Hospital

La Porte, Indiana, 46350, United States
IU Health Methodist Hospital

Indianapolis, Indiana, 46202, United States
Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401, United States
Illinois CancerCare-Peoria

Peoria, Illinois, 61615, United States
Illinois Valley Hospital

Peru, Illinois, 61354, United States
Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Intermountain Health Lutheran Hospital

Wheat Ridge, Colorado, 80401, United States
Iowa Lutheran Hospital

Des Moines, Iowa, 50316, United States
Iowa Methodist Medical Center

Des Moines, Iowa, 50309, United States
Iowa-Wide Oncology Research Coalition NCORP

Des Moines, Iowa, 50309, United States
John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Lake Huron Medical Center

Port Huron, Michigan, 48060, United States
Lake Region Healthcare Corporation-Cancer Care

Fergus Falls, Minnesota, 56537, United States
Lakeview Hospital

Stillwater, Minnesota, 55082, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, 31405, United States
Lima Memorial Hospital

Lima, Ohio, 45804, United States
Longmont United Hospital

Longmont, Colorado, 80501, United States
Mason District Hospital

Havana, Illinois, 62644, United States
Mater Misericordiae University Hospital

Dublin, Co Dublin, 7, Ireland
Mater Private Hospital

Dublin, Co Dublin, 7, Ireland
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
McFarland Clinic - Ames

Ames, Iowa, 50010, United States
Mcdonough District Hospital

Macomb, Illinois, 61455, United States
Memorial Hospital

Carthage, Illinois, 62321, United States
Memorial Hospital of South Bend

South Bend, Indiana, 46601, United States
Memorial Medical Center-Las Cruces

Las Cruces, New Mexico, 88011, United States
Mercy Cancer Center-Elyria

Elyria, Ohio, 44035, United States
Mercy Health - Saint Anne Hospital

Toledo, Ohio, 43623, United States
Mercy Health - Saint Vincent Hospital

Toledo, Ohio, 43608, United States
Mercy Hospital

Coon Rapids, Minnesota, 55433, United States
Mercy Hospital of Tiffin

Tiffin, Ohio, 44883, United States
Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314, United States
Mercy Medical Center-Sioux City

Sioux City, Iowa, 51102, United States
Mercy Memorial Hospital

Monroe, Michigan, 48162, United States
Methodist Medical Center of Illinois

Peoria, Illinois, 61636, United States
Metro Minnesota Community Oncology Research Consortium

Saint Louis Park, Minnesota, 55416, United States
MetroHealth Medical Center

Cleveland, Ohio, 44109, United States
Michigan Cancer Research Consortium NCORP

Ann Arbor, Michigan, 48106, United States
Miller-Dwan Hospital

Duluth, Minnesota, 55805, United States
Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109, United States
Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125, United States
Mount Sinai Union Square

New York, New York, 10003, United States
MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601, United States
Nevada Cancer Research Foundation NCORP

Las Vegas, Nevada, 89120, United States
New Ulm Medical Center

New Ulm, Minnesota, 56073, United States
North Coast Cancer Care

Sandusky, Ohio, 44870, United States
North Coast Cancer Care-Clyde

Clyde, Ohio, 43410, United States
North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422, United States
North Suburban Medical Center

Thornton, Colorado, 80229, United States
NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201, United States
Northern Indiana Cancer Research Consortium

South Bend, Indiana, 46628, United States
OSF Saint Francis Medical Center

Peoria, Illinois, 61637, United States
OSF Saint Francis Radiation Oncology at Pekin

Pekin, Illinois, 61554, United States
OSF Saint Joseph Medical Center

Bloomington, Illinois, 61701, United States
Ottawa Regional Hospital and Healthcare Center

Ottawa, Illinois, 61350, United States
Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416, United States
Parkland Memorial Hospital

Dallas, Texas, 75235, United States
Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907, United States
Perry Memorial Hospital

Princeton, Illinois, 61356, United States
Poudre Valley Hospital

Fort Collins, Colorado, 80524, United States
Presbyterian - Saint Lukes Medical Center - Health One

Denver, Colorado, 80218, United States
ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066, United States
ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, 53188, United States
ProMedica Flower Hospital

Sylvania, Ohio, 43560, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo, Ohio, 43606, United States
Proctor Hospital

Peoria, Illinois, 61614, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
Rice Memorial Hospital

Willmar, Minnesota, 56201, United States
Richard L. Roudebush Veterans Affairs Medical Center

Indianapolis, Indiana, 46202, United States
Ridgeview Medical Center

Waconia, Minnesota, 55387, United States
Rose Medical Center

Denver, Colorado, 80220, United States
Rush-Copley Medical Center

Aurora, Illinois, 60504, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706, United States
Saint Charles Hospital

Oregon, Ohio, 43616, United States
Saint Francis Medical Center

Cape Girardeau, Missouri, 63703, United States
Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379, United States
Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109, United States
Saint Joseph Hospital - Cancer Centers of Colorado

Denver, Colorado, 80218, United States
Saint Joseph Regional Medical Center-Mishawaka

Mishawaka, Indiana, 46545, United States
Saint Luke's Hospital

Maumee, Ohio, 43537, United States
Saint Luke's Regional Medical Center

Sioux City, Iowa, 51104, United States
Saint Mary Corwin Medical Center

Pueblo, Colorado, 81004, United States
Saint Mary Medical and Regional Cancer Center

Langhorne, Pennsylvania, 19047, United States
Saint Mary's Hospital and Regional Medical Center

Grand Junction, Colorado, 81501, United States
Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301, United States
Saint Vincent's University Hospital

Dublin, Co Dublin, 4, Ireland
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Sidney and Lois Eskenazi Hospital

Indianapolis, Indiana, 46202, United States
Siouxland Regional Cancer Center

Sioux City, Iowa, 51101, United States
Sky Ridge Medical Center

Lone Tree, Colorado, 80124, United States
Smilow Cancer Hospital Care Center at Saint Francis

Hartford, Connecticut, 06105, United States
South Bend Clinic

South Bend, Indiana, 46617, United States
Springfield Memorial Hospital

Springfield, Illinois, 62781, United States
Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States
Swedish American Hospital

Rockford, Illinois, 61104, United States
Swedish Medical Center

Englewood, Colorado, 80113, United States
Tallaght University Hospital

Dublin, Co Dublin, 24, Ireland
The Medical Center of Aurora

Aurora, Colorado, 80012, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
Toledo Clinic Cancer Centers-Bowling Green

Bowling Green, Ohio, 43402, United States
Toledo Clinic Cancer Centers-Maumee

Maumee, Ohio, 43537, United States
Toledo Clinic Cancer Centers-Monroe

Monroe, Michigan, 48162, United States
Toledo Clinic Cancer Centers-Oregon

Oregon, Ohio, 43616, United States
Toledo Clinic Cancer Centers-Toledo

Toledo, Ohio, 43623, United States
Toledo Community Hospital Oncology Program CCOP

Toledo, Ohio, 43617, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106, United States
Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341, United States
Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States
Trinity Medical Center

Moline, Illinois, 61265, United States
Trinity's Tony Teramana Cancer Center

Steubenville, Ohio, 43952, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309, United States
UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314, United States
UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325, United States
UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
United Hospital

Saint Paul, Minnesota, 55102, United States
Unity Hospital

Fridley, Minnesota, 55432, United States
University College Hospital Galway

Galway, Co Galway, Ireland
University of Maryland Shore Medical Center at Easton

Easton, Maryland, 21601, United States
University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912, United States
University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106, United States
University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Toledo

Toledo, Ohio, 43614, United States
VA Palo Alto Health Care System

Palo Alto, California, 94304, United States
Veterans Adminstration New Jersey Health Care System

East Orange, New Jersey, 07018-1095, United States
West Michigan Cancer Center

Kalamazoo, Michigan, 49007, United States
Western States Cancer Research NCORP

Denver, Colorado, 80222, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.